[Back to Overwiew]  [IACM Homepage]

IACM-Bulletin of 11 November 2018

USA: Utah and Missouri legalise the medical use of cannabis, Michigan approves recreational use

Legalization of cannabis in some form was approved by three more states on 6 November. Michigan voters favoured legalizing recreational-use cannabis, while Utah and Missouri passed propositions on medical cannabis. Michigan already has a law allowing and regulating medical cannabis.

Utah voters passed Proposition 2 with 53 percent. Governor Gary Herbert said a special legislative session will be called to have the law enacted. The compromise law has a more narrowly-defined definition of chronic pain and doesn't allow users to grow cannabis plants. Missouri voters approved one of three medical cannabis laws on the November ballot. Amendment 2 passed with about 65 percent.

UPI of 7 November 2018

Science/Human: Cannabis may be helpful in the treatment of children with autism in an open study

Cannabis with a ratio of CBD to THC of 20:1 and 6:1 was beneficial in children with autism spectrum disorder. Results of this research by doctors of the Neuropediatric Unit of the Shaare Zedek Medical Centre in Jerusalem, Israel, were published in the Journal of Autism and Developmental Disorders. Sixty patients aged 5 to 18 years received up to 10 mg/kg bodyweight of CBD and 0.5 mg/kg of THC. In 29 patients with an insufficient response to the extract with the 20:1 ratio higher THC doses were given. Mean total daily dose was 3.8 mg/kg CBD and 0.29 mg/kg THC.

Following cannabis treatment, behavioural outbreaks were much improved or very much improved in 61% of patients. Authors wrote, that “this preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.” However, the denomination of the extract as “cannabidiol-rich” may be questionable since a daily dose of 0.3 mg/kg THC may be a considerable dose for children, which is underlined by a transient serious psychotic event in one patient. Thus, treatment effects may not be based on CBD but on THC.

Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. J Autism Dev Disord. 2018 Oct 31. [in press]

Mexico: Mexico Supreme Court calls ban on recreational cannabis use unconstitutional

On 31 October Mexico’s Supreme Court ruled that an absolute ban on recreational use of cannabis was unconstitutional, effectively leaving it to lawmakers to regulate consumption of the drug. That creates a precedent other Mexican courts will have to follow. Congress would now have to act to regulate the use of cannabis in Mexico.

In a statement, the court said the ruling did not create an absolute right to use marijuana and that consumption of certain substances could still be subject to regulation. “But the effects caused by marijuana do not justify an absolute prohibition on its consumption,” it said. The court ordered federal health regulator COFEPRIS to authorize people seeking the right to use cannabis to do so personally, “albeit without allowing them to market it, or use other narcotics or psychotropic drugs.”

Reuters of 1 November 2018

UK: Cannabis may now be used for certain medical conditions

From 1 November on cannabis-based products can be prescribed, but only by consultant medical practitioners at hospitals, and only in a small number of cases, such as nausea caused by chemotherapy, muscle stiffness linked to multiple sclerosis, and for children with rare or severe forms of epilepsy. New guidelines state that medicines containing cannabis cannot be prescribed by a general practitioner, although they will be able to refer their patients to specialists to request prescriptions.

A majority of Britons (59%) support general legalisation of the drug, while 31% oppose it according to a poll commissioned by the think tank Volteface and the Centre for Medicinal Cannabis, and carried out by Populus.

The Week of 1 November 2018
The Independent of 29 October 2018

News in brief

UN: New report on the ongoing cannabis review process
FAAAT has published volume 1 of the Crimson Digest, a 50-pages condensed info about the WHO, the ongoing cannabis review process and a historical background. The second Volume to come soon will address more directly the current state of the process.
Crimson Digest
International Cannabis Policy Conference

Australia: An increasing number of patients are allowed to use cannabis for medical purposes
About 7 people a day are being approved for medicinal cannabis. Access to the drug is still severely restricted two years after its medicinal use was legalised nationally but a new online application system has increased approvals in recent months. The Therapeutic Goods Administration approved 469 applications for the drug under the Special Access Scheme between August and September. That’s up from just 97 between January and February.
News.com of 29 October 2018

Brazil: New president supports killing of drug traffickers
Jair Bolsonaro, the new president of Brazil and a supporter of Brazil’s former military dictatorship, routinely says that Brazilian police should kill suspected drug traffickers and other criminals at will. He draws his inspiration from President Rodrigo Duterte of the Philippines, whose approach has led to over 12,000 deaths of people for alleged involvement with drugs. Bolsonaro has said that Duterte “did the right thing for his country”.
Telegraph of 6 September 2018

Brazil: Judge rules that parents may grow cannabis for their sick child
Parents of a 4-year old Brazilian who suffers from cerebral palsy and West syndrome obtained permission from a judge in the region of Minas Gerais to grow enough cannabis to produce medicine from the plant. Judge Antonio Jose Pecego, a criminal court jurist in Uberlandia, the second largest municipality in the state of Minas Gerais in southeastern Brazil, justified the decision by characterizing it as a protection of the rights to life, dignity and health.
UPI of 6 November 2018

USA: CBD extract now available for the treatment of certain forms of epilepsy
Epidiolex, an oral solution of a CBD extract is now available as a treatment for seizures in patients age 2 or older who have Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex is developed by GW Pharmaceuticals and will be marketed in the U.S. by its subsidiary, Greenwich Biosciences.
Dravet Syndrome News of 7 November 2018

Science/Human: Running and singing may increase endocannabinoid blood levels
Circulating levels of the endocannabinoid were measured in 9 healthy female volunteers were measured before and immediately after 30 min of dance, reading, singing or cycling in a fasted state. Authors concluded, that “increases in endocannabinoids may underlie the rewarding and pleasurable effects of singing and exercise, and ultimately some of the long-term beneficial effects on mental health, cognition and memory.”
University of Nottingham, UK.
Stone N, et al. Front. Behav. Neurosci. 22 Oct 2018. [in press]

Science/Human: A high-fat meal may increase blood concentration of CBD by up to 5-fold
In a study with healthy adult volunteers researchers investigated safety, tolerability and pharmacokinetics of CBD oral solution up to a dose of 1500 mg CBD twice-daily. A high-fat meal increased CBD plasma concentration after the intake of 750 mg and 1500 mg twice daily by 4.85 and 4.2-fold. CBD was generally well tolerated. There were no severe side-effects.
GW Research Ltd, Cambridge, UK.
Taylor L, et al. CNS Drugs. 2018 Oct 30. [in press]

Science/Human: About 12% of frequent cannabis users experience a withdrawal syndrome
In a group of 1527 frequent cannabis users (3 or more times a week) 12.1 % of those who stopped use experienced a cannabis withdrawal syndrome. The most common withdrawal symptoms were nervousness/anxiety (76.3%), hostility (71.9%), sleep difficulty (68.2%) and depressed mood (58.9%).
Lev Hasharon Medical Center, Netanya, Israel.
Livne O, et al. Drug Alcohol Depend. 2018 Oct 16. [in press]

Science: Outlook on the use of cannabinoids in neurology
A review on medicinal properties of certain cannabinoids (THC, caryophyllene, THCA, CBD, CBDA) comes to the conclusion that they may not only be useful in the treatment of certain neurological symptoms, but may be beneficial in the treatment of underlying causes of epilepsy, brain tumours, Parkinson’s disease, Alzheimer’s disease and traumatic brain injury and may even be used in preventive treatment.
International Cannabis and Cannabinoids Institute (ICCI), Prague, Czech Republic.
Russo EB, et al. Front Integr Neurosci. 2018;12:51.

Science/Human: CBD is similar effective as established antiepileptic drugs
According to a review cannabidiol (CBD) shows similar efficacy in severe paediatric epilepsies to other antiepileptic drugs. Careful down-titration of benzodiazepines is essential to minimize sedation with adjunctive CBD.
University of Otago, Wellington, New Zealand.
Ali S, et al. Dev Med Child Neurol. 2018 Nov 6. [in press]

Science/Animal: A cannabinoid in liverwort binds to the CB1 receptor
The liverwort Radula genus contains a compound (bibenzyl (-)-cis-perrottetinene), which structurally resembles THC of the cannabis plant. Researchers demonstrated that this liverwort cannabinoid also binds to the cannabinoid-1 receptor in mice.
Institute of Biochemistry and Molecular Medicine, Bern, Switzerland.
Chicca A, et al. Sci Adv. 2018;4(10):eaat2166.

Science/Human: Cannabis use in pregnant women increased in Canada
Cannabis use by pregnant women increased from 1.2% in 2012 to 1.8% in 2017, mainly in young women and low socio-economic status.
Ottawa Hospital Research Institute, Canada.
Corsi DJ, et al. Can J Public Health. 2018 Nov 1. [in press]

Science/Human: Differences between medical and recreational cannabis users with regard to withdrawal
According to a survey of 2905 cannabis users, relative to recreational users, medical users were less likely to report undesirable acute effects but were more likely to report undesirable withdrawal symptoms. Older (50+) individuals reported fewer undesirable acute effects and withdrawal symptoms compared with younger users (18-29).
University of California San Diego, USA.
Sexton M, et. al J Altern Complement Med. 2018 Oct 31. [in press]

Science/Animal: Activation of the CB1 receptor may reduce production of gastric acid
In a study with rats activation of the CB1 receptor and antagonism at the CB2 receptor may reduce gastric acid secretion.
Toxicology and Narcotics Department, Cairo, Egypt.
Salama RAA, et al. J Biochem Mol Toxicol. 2018 Nov 1. [in press]

A glimpse @ the past

One year ago

Two years ago

[Back to Overwiew]  [IACM Homepage]

up

Online Events 2020

Please find all information of IACM Online Events including free videos of the webinars here.

Conference 2022

The 12th IACM Conference on Cannabinoids in Medicine will be we be held on 20 and 21 October 2022 together with the Swiss SSCM in Basel/Switzerland.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.